Second, although preclinical data has shown that CDK4/6 inhibitors can stimulate immune-related effects34,35, this has not been well-studied in patients or within different tumor intrinsic subtypes, and the early disease setting represents the perfect context to evaluate this phenomenon. This evidence concerns the gene CDK4 and neoplasm.